Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest Imaging.

[1]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[2]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[3]  S. Giordano,et al.  Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  M. Ahn,et al.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Henry S. Park,et al.  Strengths and limitations of large databases in lung cancer radiation oncology research. , 2019, Translational lung cancer research.

[6]  Derek E. Smith,et al.  Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Ryan P. Merkow,et al.  Practical Guide to Surgical Data Sets: National Cancer Database (NCDB) , 2018, JAMA surgery.

[8]  A. Bankier,et al.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. , 2017, Radiology.

[9]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  S. Ackerman,et al.  Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: Is the accuracy affected by breast density or cancer subtype? , 2016, Journal of clinical ultrasound : JCU.

[11]  M. Lee,et al.  Size Discrepancy Between Sonographic and Computed Tomographic/Magnetic Resonance Imaging Measurement of Hepatocellular Carcinoma , 2013, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[12]  L. Tanoue,et al.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[13]  Ali O. Farooqi,et al.  Lung cancers diagnosed at annual CT screening: volume doubling times. , 2012, Radiology.

[14]  Rebecca M. Lindell,et al.  5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. , 2009, Chest.

[15]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Mark Tann,et al.  Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. , 2006, Radiology.

[17]  N. O'Rourke,et al.  Lung cancer treatment waiting times and tumour growth. , 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[19]  A. Sakurada,et al.  Tumor doubling time and prognostic assessment of patients with primary lung cancer , 1994, Cancer.